
-
Geron Corporation NasdaqGS:GERN Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Location: 919 East Hillsdale Boulevard, Suite 250, Foster City, CA, 94404, United States | Website: https://www.geron.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
667.5M
Cash
396.9M
Avg Qtr Burn
-51.09M
Short % of Float
12.49%
Insider Ownership
0.09%
Institutional Own.
81.06%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
RYTELO™ (Imetelstat) (GRN163L) Details Myelodysplastic syndrome | Approved Quarterly sales | |
Imetelstat (GRN163L) Details Myelofibrosis | Phase 3 Interim Update | |
Imetelstat (GRN163L) Details Myelodysplastic syndrome, Acute myeloid leukemia | Phase 2 Data readout | |
Imetelstat (GRN163L)+ ruxolitinib Details Myelofibrosis | Phase 1b Data readout |